Maple syrup urine disease (MSUD) is a rare inherited metabolic disorder in which the body cannot properly break down three essential amino acids found in protein: leucine, isoleucine, and valine. These amino acids, collectively called branched-chain amino acids (BCAAs), build up in the blood and become toxic, particularly to the brain. The condition gets its name from the distinctive sweet, maple syrup-like smell that appears in an affected baby’s earwax and urine shortly after birth.
Worldwide, MSUD occurs in roughly 1 in 225,000 live births. In certain genetically isolated communities, such as Old Order Mennonite populations, the incidence is dramatically higher: about 1 in 150 births.
How MSUD Affects the Body
Every time you eat protein, your body breaks it down into individual amino acids. Three of those, leucine, isoleucine, and valine, require a specific enzyme complex called BCKDH to be processed further inside the cell’s mitochondria. This enzyme complex has multiple components (called E1, E2, and E3) that work together in sequence to convert these amino acids into usable energy building blocks.
In MSUD, a genetic mutation cripples one of those components, and the entire breakdown process stalls. The three amino acids and their partially processed byproducts accumulate in the blood and tissues. Leucine is the most dangerous of the three. At high concentrations, it causes swelling in the brain, disrupts normal nerve cell function, and can lead to irreversible neurological damage or death.
Genetics and Inheritance
MSUD follows an autosomal recessive inheritance pattern, meaning a child must inherit a faulty gene copy from both parents to develop the disease. Four genes can be responsible: BCKDHA, BCKDHB, DBT, and DLD. Each one encodes a different piece of the BCKDH enzyme complex. A mutation in any one of these genes can be enough to break the entire system. Parents who each carry one defective copy are typically healthy and unaware they are carriers.
The Four Types of MSUD
Classic MSUD
This is the most common and most severe form. The enzyme retains virtually no function (0% to 2% of normal activity). Babies with classic MSUD appear healthy at birth but begin showing symptoms within the first 10 days of life. The maple syrup odor can be detected in earwax as early as 12 hours after birth and in urine by the end of the first week. Within 48 to 72 hours, nonspecific signs appear: lethargy, poor feeding, vomiting, and irritability. Brain involvement follows two to three days later, with worsening drowsiness, breathing pauses, seizures, and changes in muscle tone. By 7 to 10 days, untreated infants can slip into a coma. Without intervention, death typically occurs within two months.
Intermediate MSUD
Children with intermediate MSUD retain 3% to 30% of normal enzyme activity. The age of onset varies, and symptoms are less acute but still serious: poor growth, feeding difficulties, developmental delays, and the characteristic odor. These children are vulnerable to brain injury during illness or other physical stress, even if they appear relatively stable day to day.
Intermittent MSUD
This form is deceptive. Children grow and develop normally in early life, and their amino acid levels look fine when they are well. But during an infection, surgery, or period of fasting, the system becomes overwhelmed and amino acid levels spike to dangerous levels, producing a crisis that looks identical to classic MSUD. Enzyme activity ranges from 5% to 20% of normal.
Thiamine-Responsive MSUD
A rare subtype that resembles the intermediate form but shows measurable improvement when treated with high doses of thiamine (vitamin B1). Enzyme activity varies widely, from 2% to 40% of normal. These individuals still need dietary management, but thiamine supplementation increases their tolerance for protein.
How MSUD Is Diagnosed
In many countries, MSUD is part of standard newborn screening. A blood sample taken from the baby’s heel within the first day or two of life can detect elevated levels of leucine, isoleucine, and valine. A key diagnostic marker is the presence of alloisoleucine, an abnormal amino acid that does not appear in healthy individuals. Its detection in a blood sample is essentially diagnostic for MSUD.
Early detection through newborn screening makes an enormous difference. A meta-analysis published in Genetics in Medicine found that babies identified through screening had a mean IQ of 95, compared to 82 for those diagnosed only after symptoms appeared. Mortality was also dramatically lower: 3% in the screened group versus nearly 15% in those diagnosed late.
Daily Dietary Management
The cornerstone of MSUD treatment is strict, lifelong restriction of leucine, isoleucine, and valine intake. Because these amino acids are found in virtually all dietary protein, this means carefully measured portions of natural protein combined with a special medical formula that provides all other amino acids the body needs but contains zero BCAAs.
The amount of leucine a person with MSUD can tolerate changes with age. Newborns and infants can generally handle 65 to 85 milligrams of leucine per kilogram of body weight each day. For children, that drops to 20 to 40 mg/kg/day, and adults typically tolerate only 10 to 15 mg/kg/day. These limits are tight. A single glass of milk or a serving of chicken contains far more leucine than many MSUD patients can safely consume in an entire day. Blood amino acid levels need to be monitored regularly to keep them in a safe range.
Even with excellent dietary control, any situation that increases the body’s protein breakdown, like a fever, stomach virus, skipped meals, or surgery, can trigger a dangerous spike in leucine levels. Families learn to recognize the early warning signs of a metabolic crisis: extreme tiredness, irritability, vomiting, and loss of alertness. These episodes require immediate medical attention, often involving intravenous fluids with glucose and specialized amino acid solutions to drive leucine levels back down.
Liver Transplantation
Because the liver is a major site of BCAA metabolism, liver transplantation can fundamentally change the course of classic MSUD. A transplanted liver provides enough working enzyme to stabilize amino acid levels, even though other tissues in the body still carry the genetic defect.
Results have been striking. In a study of 37 patients with classic MSUD who received liver transplants, patient and graft survival were both 100% at an average follow-up of 4.5 years. Across all 54 MSUD liver transplants performed in the United States between 2004 and 2010, patient survival was 98% and graft survival was 96%. After transplantation, leucine tolerance increased more than tenfold, allowing patients to eat an unrestricted diet with normal protein intake for the first time in their lives. Amino acid levels remained stable even during illness.
An interesting feature of MSUD liver transplants is the possibility of “domino” donation: the removed MSUD liver can be transplanted into a patient dying of liver failure from another cause. Because the rest of that recipient’s body has normal BCAA metabolism, the MSUD liver functions well enough. All six domino recipients in the study were alive and well with normal amino acid levels on unrestricted diets.
Long-Term Outlook
With early diagnosis, careful dietary management, and access to quality healthcare, many people with MSUD live into adulthood. The quality of the national healthcare system a person is born into correlates significantly with both survival and the likelihood of permanent neurological symptoms. Children diagnosed through newborn screening and treated promptly have near-normal cognitive outcomes on average, though they remain at risk for setbacks during metabolic crises throughout life.
The ongoing challenge is vigilance. Every illness, growth spurt, or period of stress is a potential trigger, and the margin for error is slim. Families managing MSUD typically work closely with metabolic specialists, dietitians, and emergency teams who understand the condition. For those with classic MSUD who can access it, liver transplantation offers a path to dietary freedom and significantly reduced risk of metabolic crises.